Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report)’s share price dropped 21.1% on Thursday . The company traded as low as $0.6204 and last traded at $0.65. Approximately 110,106 shares changed hands during trading, a decline of 93% from the average session volume of 1,521,488 shares. The stock had previously closed at $0.8236.
Qualigen Therapeutics Trading Down 1.3%
The company has a 50-day moving average price of $1.12 and a two-hundred day moving average price of $1.35. The stock has a market capitalization of $1.12 million, a P/E ratio of -0.09 and a beta of 0.24.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Featured Stories
- Five stocks we like better than Qualigen Therapeutics
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
- MarketBeat Week in Review – 07/27- 07/31
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
